Oxeia Biopharmaceuticals, Inc. (OXEA)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	-1.97M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About OXEA

Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Our first two indications are for (i) mild traumatic brain injury, known as concussion, and (ii) the cognitive decline, lethargy and “brain-fog” associated with Covid-19 infection, known as Covid Longhauler syndrome (“Long Covid”). On May 1, 2017, we acquired certain rights to a ghrelin molecule OXE103 that was originally developed by Daiichi Sankyo f...

• Industry: Health Care
• Sector: Biotechnology
• Founded: 2014
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: OXEA